Mdm4 protein
Homo sapiens
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein heterocomplex Heteromer Protein × 2 PDB declaration: dimeric(2) Consistent with protein copy count | Chain A; UniProt 14–111 | Fragment:N-terminal domain, UNP residues 14-111 Mutation:C17S | p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-6-Cl-Trp-Glu-Ac3c-Leu-NH2 × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 1 | X-RAY DIFFRACTION X-ray crystallization conditions:VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;3.1M AmSo4, 1% MPD, 0.1M MES, pH6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K | Resolution 1.33 Å R-free 0.206 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 3FEA | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 2CR8 Solution structure of the zf-RanBP domain of p53-binding protein Mdm4 Deposited 2005-05-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
300–339(40 aa)
Fragment:zf-RanBP domain
|
Not recorded | ZN ZINC ION × 1 |
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 120mM;Pressure ambient
NMR sample composition
0.42mM 13C, 15N-labeled protein; 20mM d-Tris-HCl (pH7.0); 200mM NaCl; 1mM d-DTT; 0.02% NaN3; 0.01mM ZnCl2 | 90% H2O/10% D2O
|
Resolution not provided |
| 2MWY Mdmx-p53 Deposited 2014-12-03 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
Fragment:SWIB domain residues 23-111
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 200;Pressure ambient
NMR sample composition
1.0 mM [U-100% 13C; U-100% 15N] protein 1, 1.2 mM protein 2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N06 Mdmx-298 Deposited 2015-03-04 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | 44Z 4-[[(4S,5R)-5-(4-chlorophenyl)-4-(3-methoxyphenyl)-2-(4-methoxy-2-propan-2-yloxy-phenyl)-4,5-dihydroimidazol-1-yl]carbonyl]piperazin-2-one × 1 |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 200;Pressure ambient
NMR sample composition
1.0 mM [U-100% 13C; U-100% 15N] entity_1-1, 1.0 mM SJ298-2, 0.2 mM sodium chloride-3, 0.01 mM DTT-4, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N0U Mdmx-057 Deposited 2015-03-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | 48M 4-[(4S,5R)-4-(3-chlorophenyl)-5-(4-chlorophenyl)-1-(3-oxidanylidenepiperazin-1-yl)carbonyl-4,5-dihydroimidazol-2-yl]-3-propan-2-yloxy-benzenecarbonitrile × 1 |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 200;Pressure ambient
NMR sample composition
0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N0W Mdmx-SJ212 Deposited 2015-03-17 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | 48L 4-({(4S,5R)-4-(5-bromo-2-fluorophenyl)-5-(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 200;Pressure ambient
NMR sample composition
0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2N14 Mdmx-295 Deposited 2015-03-20 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | 49H 4-({(4S,5R)-4-(3-chlorophenyl)-5-(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 |
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 200;Pressure ambient
NMR sample composition
0.5 mM [U-100% 13C; U-100% 15N] protein_1, 0.6 mM protein_2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2VJE Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Deposited 2007-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
428–490(63 aa)
Fragment:RESIDUES 428-490
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
|
Resolution 2.20 Å R-free 0.223 |
| 2VJE Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Deposited 2007-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain D
428–490(63 aa)
Fragment:RESIDUES 428-490
|
Not recorded | ZN ZINC ION × 4 FLC CITRATE ANION × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
|
Resolution 2.20 Å R-free 0.223 |
| 2VJF Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Deposited 2007-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
428–490(63 aa)
Fragment:RESIDUES 428-490
|
Not recorded | ZN ZINC ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
|
Resolution 2.30 Å R-free 0.234 |
| 2VJF Crystal Structure of the MDM2-MDMX RING Domain Heterodimer Deposited 2007-12-10 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain D
428–490(63 aa)
Fragment:RESIDUES 428-490
|
Not recorded | ZN ZINC ION × 4 FLC CITRATE ANION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;1.8 M NH4(SO4)2, 0.5 M NACL, 0.1 M NA CITRATE, PH 6.5
|
Resolution 2.30 Å R-free 0.234 |
| 2VYR Structure of human MDM4 N-terminal domain bound to a single domain antibody Deposited 2008-07-28 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 12 PDB declaration: dodecameric |
Chain A
16–116(101 aa)
Fragment:RESIDUES 16-116
Chain B
16–116(101 aa)
Fragment:RESIDUES 16-116
Chain C
16–116(101 aa)
Fragment:RESIDUES 16-116
Chain D
16–116(101 aa)
Fragment:RESIDUES 16-116
|
Not recorded | SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7;SE-MET: 20% PEG 3350, 0.2 M MGCL2, 1MM TRIS PH 7.0, 5MM B-ME, PROTEIN 10MG/ML. NATIVE: 1.6M AMMONIUM SULPHATE, 0.5M LITHIUM CHLORIDE, 1MM TRIS, PH 7.0, 5MM B-ME, PROTEIN 10MG/ML
|
Resolution 2.00 Å R-free 0.248 |
| 3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Deposited 2008-05-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 1.90 Å R-free 0.257 |
| 3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Deposited 2008-05-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 1.90 Å R-free 0.257 |
| 3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Deposited 2008-05-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 1.90 Å R-free 0.257 |
| 3DAB Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Deposited 2008-05-29 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain G
23–111(89 aa)
Fragment:UNP residues 23-111
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;300 K;25% PEG3350, 0.1M MES, pH6.5, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 1.90 Å R-free 0.257 |
| 3EQY Crystal structure of human MDMX in complex with a 12-mer peptide inhibitor Deposited 2008-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–108(85 aa)
Fragment:UNP residues residues 24-108
|
Mutation:Q68A, Q69A, E70A | GAI GUANIDINE × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1M HEPES, 0.8 M sodium phosphate, 0.8 M potassium phosphate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.63 Å R-free 0.169 |
| 3EQY Crystal structure of human MDMX in complex with a 12-mer peptide inhibitor Deposited 2008-10-01 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
24–108(85 aa)
Fragment:UNP residues residues 24-108
|
Mutation:Q68A, Q69A, E70A | GAI GUANIDINE × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0.1M HEPES, 0.8 M sodium phosphate, 0.8 M potassium phosphate, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.63 Å R-free 0.169 |
| 3FDO Structure of human MDMX in complex with high affinity peptide Deposited 2008-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
Fragment:p53 binding domain, UNP residues 23-111
|
Not recorded | MG MAGNESIUM ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
|
Resolution 1.40 Å R-free 0.247 |
| 3FDO Structure of human MDMX in complex with high affinity peptide Deposited 2008-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
23–111(89 aa)
Fragment:p53 binding domain, UNP residues 23-111
|
Not recorded | MG MAGNESIUM ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
|
Resolution 1.40 Å R-free 0.247 |
| 3FDO Structure of human MDMX in complex with high affinity peptide Deposited 2008-11-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain A
23–111(89 aa)
Fragment:p53 binding domain, UNP residues 23-111
|
Not recorded | MG MAGNESIUM ION × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.3;290 K;4.3M NaCl, 100mM Hepes, pH7.3, VAPOR DIFFUSION, SITTING DROP, temperature 290K
|
Resolution 1.40 Å R-free 0.247 |
| 3FE7 Crystal Structure of HdmX bound to the p53-peptidomimetic Ac-Phe-Met-Aib-Pmp-Trp-Glu-Ac3c-Leu-NH2 at 1.35A Deposited 2008-11-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, UNP residues 14-111
|
Mutation:C17S | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;277 K;3.1M AmSo4, 1% MPD, 4% polypropyleneglycol, 0.1M MES, pH6.0, VAPOR DIFFUSION, HANGING DROP, temperature 277K
|
Resolution 1.35 Å R-free 0.209 |
| 3JZO Human MDMX liganded with a 12mer peptide (pDI) Deposited 2009-09-23 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
|
Not recorded | K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.2;292 K;1.4 M Na/K phosphate, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.80 Å R-free 0.207 |
| 3JZP Human MDMX liganded with a 12mer peptide inhibitor (pDI6W) Deposited 2009-09-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
|
Not recorded | K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.2;292 K;1.4 M Na/K phosphate, pH 8.2, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.74 Å R-free 0.217 |
| 3JZQ Human MDMX liganded with a 12mer peptide inhibitor (pDIQ) Deposited 2009-09-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.4;292 K;2.1 M ammonium sulfate, 10 mM Tris HCl, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.80 Å R-free 0.224 |
| 3JZQ Human MDMX liganded with a 12mer peptide inhibitor (pDIQ) Deposited 2009-09-24 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
23–111(89 aa)
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.4;292 K;2.1 M ammonium sulfate, 10 mM Tris HCl, pH 7.4, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 1.80 Å R-free 0.224 |
| 3LBJ Structure of human MDMX protein in complex with a small molecule inhibitor Deposited 2010-01-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain E
23–111(89 aa)
Fragment:p53 binding domain
|
Not recorded | WW8 N-[(3S)-1-({6-chloro-3-[1-(4-chlorobenzyl)-4-phenyl-1H-imidazol-5-yl]-1H-indol-2-yl}carbonyl)pyrrolidin-3-yl]-N,N',N'-trimethylpropane-1,3-diamine × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 5.6;300 K;0.2M Na/K-tartrate, 0.1M Tri-sodium-citrate, 2M ammonium sulfate, pH 5.6, VAPOR DIFFUSION, SITTING DROP, temperature 300K
|
Resolution 1.50 Å R-free 0.206 |
| 3U15 Structure of hDMX with Dimer Inducing Indolyl Hydantoin RO-2443 Deposited 2011-09-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain A
14–111(98 aa)
Fragment:unp residues 14-111
Chain B
14–111(98 aa)
Fragment:unp residues 14-111
|
Mutation:C17S Mutation:C17S | 03M (5Z)-5-[(6-chloro-7-methyl-1H-indol-3-yl)methylidene]-3-(3,4-difluorobenzyl)imidazolidine-2,4-dione × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;1.4-2.0M ammonium sulfate
1.4-2.0M NaCl, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å R-free 0.238 |
| 3U15 Structure of hDMX with Dimer Inducing Indolyl Hydantoin RO-2443 Deposited 2011-09-29 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein homooligomer Homooligomer;Protein × 2 PDB declaration: dimeric |
Chain C
14–111(98 aa)
Fragment:unp residues 14-111
Chain D
14–111(98 aa)
Fragment:unp residues 14-111
|
Mutation:C17S Mutation:C17S | 03M (5Z)-5-[(6-chloro-7-methyl-1H-indol-3-yl)methylidene]-3-(3,4-difluorobenzyl)imidazolidine-2,4-dione × 2 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;277 K;1.4-2.0M ammonium sulfate
1.4-2.0M NaCl, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K
|
Resolution 1.80 Å R-free 0.238 |
| 4RXZ Crystal Structure of MDMX phosporylated Tyr99 in complex with a 12-mer peptide Deposited 2014-12-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–108(85 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;12% isopropanol, 0.1M MES pH 6.5 and 10% PEG5000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.55 Å R-free 0.220 |
| 4RXZ Crystal Structure of MDMX phosporylated Tyr99 in complex with a 12-mer peptide Deposited 2014-12-12 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
24–108(85 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;12% isopropanol, 0.1M MES pH 6.5 and 10% PEG5000 MME, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 1.55 Å R-free 0.220 |
| 5MNJ Structure of MDM2-MDMX-UbcH5B-ubiquitin complex Deposited 2016-12-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain D
427–490(64 aa)
|
Not recorded | ZN ZINC ION × 4 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;292 K;0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350
|
Resolution 2.16 Å R-free 0.231 |
| 5MNJ Structure of MDM2-MDMX-UbcH5B-ubiquitin complex Deposited 2016-12-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain H
427–490(64 aa)
|
Not recorded | ZN ZINC ION × 4 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;292 K;0.1 M Tris-HCl, pH 8.5, 0.175 M Li2SO4 and 16-20 %(v/v) PEG 3350
|
Resolution 2.16 Å R-free 0.231 |
| 5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 Deposited 2017-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A,Q69A,E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
|
Resolution 3.00 Å R-free 0.315 |
| 5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 Deposited 2017-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain B
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A,Q69A,E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
|
Resolution 3.00 Å R-free 0.315 |
| 5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 Deposited 2017-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A,Q69A,E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
|
Resolution 3.00 Å R-free 0.315 |
| 5UML CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH 12-MER PEPTIDE INHIBITOR M3 Deposited 2017-01-27 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain G
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A,Q69A,E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.6;298 K;14% (v/v) 2-Propanol ,70 mM Sodium acetate/ Hydrochloric acid pH 4.6, 140 mM Calcium chloride, 30% (v/v) Glycerol
|
Resolution 3.00 Å R-free 0.315 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain C
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain E
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain G
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 5 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain I
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 6 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain K
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 7 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain M
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 5VK1 Crystal structure of human MDM4 in complex with a 12-mer lysine-cysteine side chain dithiocarbamate stapled peptide inhibitor PMI Deposited 2017-04-20 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 8 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain O
24–108(85 aa)
Fragment:residues 24-108
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8.5;294 K;30% 2-propanol, 30% PEG 3350, and 100 mM Tris-HCl pH 8.5
|
Resolution 2.69 Å R-free 0.335 |
| 6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.10 Å R-free 0.252 |
| 6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 SO4 SULFATE ION × 1 GOL GLYCEROL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.10 Å R-free 0.252 |
| 6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.10 Å R-free 0.252 |
| 6Q9Q HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 13 AT 2.1A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 4 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain D
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HUE 6-chloranyl-3-[3-[(1~{S})-1-(4-chlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-~{N}-[2-(4-cyclohexylpiperazin-1-yl)ethyl]-1~{H}-indole-2-carboxamide × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 SO4 SULFATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.6M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.10 Å R-free 0.252 |
| 6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 4 SO4 SULFATE ION × 1 NA SODIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.40 Å R-free 0.268 |
| 6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain C
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 7 SO4 SULFATE ION × 2 NA SODIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.40 Å R-free 0.268 |
| 6Q9S HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 14 AT 2.4A: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRN 3-[[6-chloranyl-3-[3-[(1~{S})-1-(2,4-dichlorophenyl)ethyl]-5-phenyl-imidazol-4-yl]-1~{H}-indol-2-yl]carbonylamino]-4-[4-(2-oxidanylidene-1,3-oxazinan-3-yl)piperidin-1-yl]benzoic acid × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 SO4 SULFATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 6% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.40 Å R-free 0.268 |
| 6Q9U HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 12 AT 2.4A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRE 4-[(4~{S})-5-(5-chloranyl-2-oxidanylidene-1~{H}-pyridin-3-yl)-2-[2-(dimethylamino)-4-methoxy-pyrimidin-5-yl]-6-oxidanylidene-3-propan-2-yl-4~{H}-pyrrolo[3,4-c]pyrazol-4-yl]benzenecarbonitrile × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 CL CHLORIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.3M AmSO4, 2% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 2.40 Å R-free 0.265 |
| 6Q9W X-ray structure of compound 15 bound to HdmX: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRT (4~{S})-4-(4-chlorophenyl)-5-[(1~{S})-1-(3-chlorophenyl)ethyl]-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one × 1 SO4 SULFATE ION × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 1.55 Å R-free 0.240 |
| 6Q9W X-ray structure of compound 15 bound to HdmX: Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRT (4~{S})-4-(4-chlorophenyl)-5-[(1~{S})-1-(3-chlorophenyl)ethyl]-2-(2,4-dimethoxypyrimidin-5-yl)-3-propan-2-yl-4~{H}-pyrrolo[3,4-d]imidazol-6-one × 1 SO4 SULFATE ION × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;2.25M AmSO4, 4% w/v 18-crown-ether, 0.1M HEPES
|
Resolution 1.55 Å R-free 0.240 |
| 6Q9Y HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 16 AT 1.20A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRQ 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;2.5M AmSO4, 0.1M KSCN, 1% v/v MPD, 0.1M MES
|
Resolution 1.20 Å R-free 0.184 |
| 6Q9Y HDMX (14-111; C17S) COMPLEXED WITH COMPOUND 16 AT 1.20A; Structural states of Hdm2 and HdmX: X-ray elucidation of adaptations and binding interactions for different chemical compound classes Deposited 2018-12-18 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain B
14–111(98 aa)
Fragment:N-terminal domain, p53 binding domain
|
Mutation:C17S | HRQ 7-methoxy-~{N}-[(3~{S})-1-(4-methylphenyl)pyrrolidin-3-yl]-1~{H}-indole-3-carboxamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6;298 K;2.5M AmSO4, 0.1M KSCN, 1% v/v MPD, 0.1M MES
|
Resolution 1.20 Å R-free 0.184 |
| 6YR5 14-3-3 sigma in complex with hDMX-367 peptide Deposited 2020-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain O
361–374(14 aa)
Chain P
361–374(14 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;0.1M Bis-Tris propane pH 7, 0.2 M Sodium citrate, 20% PEG3350
|
Resolution 2.25 Å R-free 0.222 |
| 6YR5 14-3-3 sigma in complex with hDMX-367 peptide Deposited 2020-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain Q
361–374(14 aa)
Chain R
361–374(14 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7;277 K;0.1M Bis-Tris propane pH 7, 0.2 M Sodium citrate, 20% PEG3350
|
Resolution 2.25 Å R-free 0.222 |
| 6YR7 14-3-3 sigma in complex with hDMX-342+367 peptide Deposited 2020-04-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 4 PDB declaration: tetrameric |
Chain C
335–374(40 aa)
Chain Q
335–374(40 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF) Non-standard monomer:Yes (specific site not provided by mmCIF) | B3P 2-[3-(2-HYDROXY-1,1-DIHYDROXYMETHYL-ETHYLAMINO)-PROPYLAMINO]-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8;277 K;Sodium citrate tribasic dihydrate, PEG3350, Bis-Tris propane pH8
|
Resolution 2.10 Å R-free 0.246 |
| 7C3Q Human MdmX protein in complex with Nutlin3a Deposited 2020-05-13 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–108(86 aa)
|
Not recorded | O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1 M HEPES sodium salt pH 7.5, 1.6 M Ammonium sulfate, 2%(w/v) PEG 1000
|
Resolution 1.80 Å R-free 0.241 |
| 7C3Y Crystal structure of the N-terminal domain of human MdmX protein in complex with Nutlin3a Deposited 2020-05-14 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–108(86 aa)
|
Not recorded | O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;20% v/v Tacsimate pH 7.0, 0.1 M HEPES sodium salt pH 7.5, 2% (w/v) PEG 200
|
Resolution 1.63 Å R-free 0.227 |
| 7C44 Crystal structure of the p53-binding domain of human MdmX protein in complex with Nutlin3a Deposited 2020-05-15 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–108(86 aa)
|
Not recorded | NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;291 K;20% v/v Tacsimate pH 7.0, 0.1 M HEPES sodium salt pH 7.5, 2% (w/v) PEG 200
|
Resolution 1.65 Å R-free 0.265 |
| 7EL4 The crystal structure of p53p peptide fragment in complex with the N-terminal domain of MdmX Deposited 2021-04-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Insufficient information Monomer;Protein × 1 PDB declaration: monomeric |
Chain A
23–111(89 aa)
|
Not recorded | O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 2 MG MAGNESIUM ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.16;291 K;0.1 M MES pH 6.5, 2 M MgSO4
|
Resolution 2.11 Å R-free 0.225 |
| 7KJN CRYSTAL STRUCTURE OF HUMAN MDMX IN COMPLEX WITH D-PEPTIDE INHIBITOR (DPMI-OMEGA) Deposited 2020-10-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 3 PDB declaration: trimeric |
Chain A
24–108(85 aa)
|
Mutation:Q68A, Q69A, E70A | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;294 K;4M sodium chloride, 5% isopropanol, 0.1M HEPES pH 7.5
|
Resolution 2.80 Å R-free 0.244 |
| 7MLA Solution NMR structure of HDMX in complex with Zn and MCo-52-2 Deposited 2021-04-28 | Different construct Different mutation/modification Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
428–490(63 aa)
|
Not recorded | ZN ZINC ION × 2 |
SOLUTION NMR
NMR measurement conditions
pH 7;298 K;Ionic strength (raw mmCIF value) 0.15;Pressure 1
NMR sample composition
0.100 mM [U-100% 13C; U-100% 15N] Hdmx, 0.100 mM MCo-52-2, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
0.100 mM Hdmx, 0.100 mM [U-100% 13C; U-100% 15N] MCo-52-2, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 8IA5 Small peptide enhances the binding of nutline-3a to N-terminal domain of MdmX Deposited 2023-02-07 | Different construct Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer;Protein × 2 PDB declaration: dimeric |
Chain A
23–111(89 aa)
|
Not recorded | NUT 4-({(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one × 1 O4B 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;291 K;0.1M HEPES pH6.0, 1.6M Ammonium sulfate
|
Resolution 1.93 Å R-free 0.284 |
36 other PDB entries and 66 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | MDM4_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A; PDBConstruct 3–100; UniProt 14–111 |